SELECT PUBLICATIONS
Chau I, Cunningham D. Adjuvant therapy in colon cancer — What, when and how? Ann
Oncol 2006;[Epub ahead of print]. Abstract
De Castro G Junior et al. Angiogenesis and cancer: A cross-talk between basic science
and clinical trials (the “do ut des” paradigm). Crit Rev Oncol Hematol 2006;[Epub ahead of
print]. Abstract
De Gramont A. Rapid evolution in colorectal cancer: Therapy now and over the next
five years. Oncologist 2005;10(Suppl 2):4-8. Abstract
Ellis LM et al. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis
inhibition in solid tumor malignancies. Clin Adv Hematol Oncol 2006;4(1):Suppl 1-10.
Abstract
Goldberg RM et al. Angiogenesis inhibition in the treatment of colorectal cancer Part 3
of a 3-part series: Targeting VEGF — Current and future research directions. Clin Adv
Hematol Oncol 2005;3(12):1-10. Abstract
Jain RK et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat
Clin Pract Oncol 2006;3(1):24-40. Abstract
Love NH et al. Patient perspectives on trade-offs of adjuvant systemic therapy for Stage
II and III colon cancer: A survey of 150 people with colorectal cancer. Proc ASCO GI
2006;Abstract 373.
Wainberg Z, Hecht JR. A phase III randomized, open-label, controlled trial of chemotherapy
and bevacizumab with or without panitumumab in the first-line treatment of
patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;5(5):363-7. No abstract
available
